Large, genome-wide quantitative evaluation of DNA methylation associated with chronic kidney disease (CKD) reveals several genes with strong biological evidence for differential methylation. RNA-Seq analysis was performed using Partek® Flow® and Partek® Genomics Suite® to confirm the functional role of differential methylation in ELMO1 and PRKAG2. Findings were validated by functional enrichment using Partek® Pathway™. These results could be the first step toward identifying epigenetic therapies for CKD.
Blog - In the News
Researchers at Queen’s University of Belfast Use Partek Software in First Steps Toward Therapies for Chronic Kidney DiseaseJanuary 18, 2015
Using Partek Software in Leukemia ResearchFebruary 3, 2014
A study by Alexander Thompson, PhD of the Centre for Cancer Research and Cell Biology, Queen’s University of differential gene expression in cytogenetically normal subtype of acute myeloid leukemia cells reveals a HOX/TALE signature that may have specific prognostic value. Direct gene targeting of HOXA/PBX3 sensitizes these cells to standard chemotherapy, laying a foundation for a novel therapeutic strategy.
Recent Webinar RecordingsFebruary 3, 2014
Take a look at these recordings to see how Partek software can help in your research.
Updates in Partek SoftwareFebruary 3, 2014
Partek software supports all microarray, next generation sequencing, and qPCR platforms. Regardless of which data you are analyzing, our software will take your study from start to finish. Here are some of the latest additions to our software tools.
Tech Tip: Recommended Aligners by ApplicationFebruary 3, 2014
If you've ever wondered what aligner to use for your application, then download this handy guide compiled by our technical experts. Download now.
Recent Publications: Selected ListFebruary 3, 2014
Researchers around the world are using Partek software to make biological discoveries. Over 860 new peer reviewed articles using Partek software were published in 2013 for a total of more than 3,000 publications.
Kennedy Krieger Institute and Partek Awarded $1.8M NIH GrantMay 22, 2013
Partek Incorporated, in collaboration with the Kennedy Krieger Institute, has been awarded a phase II Small Business Innovation Research (SBIR) grant in the amount of $1.8M by the National Institutes of Health (NIH) to develop commercial software which will analyze human genetic changes and illuminate chromosomal abnormalities underlying conditions such as autism spectrum disorder (ASD), bipolar disorder, and schizophrenia.
Kennedy Krieger and Partek Incorporated Discover Novel Method to Reveal Genetic Relatedness Between IndividualsNovember 15, 2011
At a time when profound gaps remain in our understanding of how one person’s genes differ from another person’s, developing accurate methods to interpret the human genome is essential to uncover population history, population relationships and the genetic basis of some of the most common diseases affecting society.